- Home
- AIFF vs ALGS Comparison
AIFF vs ALGS Comparison
Compare AIFF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- ALGS
- Stock Information
- Founded
- AIFF 2006
- ALGS 2018
- Country
- AIFF Canada
- ALGS United States
- Employees
- AIFF N/A
- ALGS 68
- Industry
- AIFF
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- ALGS Health Care
- Exchange
- AIFF NYSE
- ALGS Nasdaq
- Market Cap
- AIFF 24.9M
- ALGS 71.0M
- IPO Year
- AIFF N/A
- ALGS 2020
- Fundamental
- Price
- AIFF $2.93
- ALGS $20.01
- Analyst Decision
- AIFF
- ALGS Strong Buy
- Analyst Count
- AIFF 0
- ALGS 1
- Target Price
- AIFF N/A
- ALGS $75.00
- AVG Volume (30 Days)
- AIFF 65.7K
- ALGS 562.3K
- Earning Date
- AIFF 11-14-2024
- ALGS 11-06-2024
- Dividend Yield
- AIFF N/A
- ALGS N/A
- EPS Growth
- AIFF N/A
- ALGS N/A
- EPS
- AIFF N/A
- ALGS N/A
- Revenue
- AIFF $74,000.00
- ALGS $5,997,000.00
- Revenue This Year
- AIFF N/A
- ALGS N/A
- Revenue Next Year
- AIFF N/A
- ALGS N/A
- P/E Ratio
- AIFF N/A
- ALGS N/A
- Revenue Growth
- AIFF N/A
- ALGS N/A
- 52 Week Low
- AIFF $2.74
- ALGS $6.76
- 52 Week High
- AIFF $15.90
- ALGS $30.00
- Technical
- Relative Strength Index (RSI)
- AIFF 42.66
- ALGS 70.57
- Support Level
- AIFF $2.92
- ALGS $14.65
- Resistance Level
- AIFF $3.36
- ALGS $24.84
- Average True Range (ATR)
- AIFF 0.34
- ALGS 3.00
- MACD
- AIFF -0.02
- ALGS 0.59
- Stochastic Oscillator
- AIFF 9.52
- ALGS 56.96
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.